IMNM

Immunome Inc.

Price

$29.83

return (12m)

197.65%

p/e

-11.72

p/bv

5.68

DIVIDEND YIELD

0.00%

IMNM price

Immunome

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment IMNM

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

32.20%

3 months

29.90%

1 year

197.65%

2 years

108.57%

5 years

138.60%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals IMNM

Valuation

P/E

-11.72

Sector -4.38

Industry -4.38

P/BV

5.68

Sector 2.02

Industry 2.02

P/Revenue (PSR)

Sector -4.40

Industry -4.40

EV/EBITDA

-31.97

Sector -263.09

Industry -263.09

EV/EBIT

-31.49

Sector -702.90

Industry -702.90

P/EBITDA

-11.16

Sector -4.39

Industry -4.39

P/EBIT

-11.02

Sector -4.73

Industry -4.73

P/Total Assets

5.27

Sector 1.49

Industry 1.49

P/Net Current Assets

5.98

Sector -11.70

Industry -11.70

P/Working Capital

5.93

Sector -3.19

Industry -3.19

EPS

-2.25

Sector -2.14

Industry -2.14

BVPS

4.65

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

0.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

0.00%

Sector -38.22%

Industry -38.22%

Net Profit Margins

0.00%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-48.44%

Sector -65.14%

Industry -65.14%

ROA

-44.98%

Sector -65.53%

Industry -65.53%

ROIC

-916.39%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

15.08

Sector 2.90

Industry 2.90

Net Debt / EBITDA

6.76

Sector -6.07

Industry -6.07

Net Debt / EBIT

6.65

Sector -8.26

Industry -8.26

Net Debt / Equity

-0.99

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.93

Sector 0.41

Industry 0.41

Liabilities/Assets

0.07

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

59.41%

Sector -

Industry -

Fundamentals IMNM

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
IMNM Immunome Inc.	$29.83	190.98%	0.00%	-11.72	5.68	-48.44%	0.00%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

IMNM Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Immunome

Immunome Inc.

Average Investor10 user rating

4.0 (1 people)

United States

20 years

Founded: 2006

2020

Time since IPO - 6 years

23

Employees

Immunome Inc. (United States) is listed on the Nasdaq and has a market capitalization of $2.98 billion, with shareholders equity totaling $525.08 million.

The company employs approximately 23 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Immunome Inc. reported $- in revenue, generating net income of $-254.33 million.

Key financial metrics include a P/E ratio of -11.72, a price-to-book (P/B) ratio of 5.68, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker IMNM.

Market cap

$2.98 billion

Net worth

$525.08 million

$525,080,000.00

Assets

$565.38 million

$565,380,000.00

Total Shares Outstanding

113.00 million

113,000,000

Average Daily Trading Volume

$1.39 million

$1,391,506.00

Sector

Health Care

Industry

Biotechnology

IMNM

IMNM revenue and profits

Financial Results IMNM

DRAG THE FRAME TO SEE MORE DATA

IMNM cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Immunome (IMNM) today?

A cotação de Immunome (IMNM) hoje está em US$ 29.83, com uma variação de 197.65% em relação ao último ano. A cotação de Immunome (IMNM) iniciou o ano negociando na casa dos US$ 21.48 e hoje está em US$ 29.83. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Immunome (IMNM) e dados de ações do Ibovespa e mercados internacionais.

Quando Immunome (IMNM) paga dividendos?

Immunome (IMNM) não distribuiu dividendos no último ano.

Is Immunome (IMNM) a good investment?

Atualmente, Immunome (IMNM) está cotada a US$ 29.83, com um P/L de -11.72, representando um desvio de -571% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 197.65 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 197.65%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Immunome (IMNM) stock?

Investir em ações de Immunome (IMNM) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Immunome (IMNM) yield today?

A rentabilidade de Immunome (IMNM) foi de 32.20% no último mês, 197.65% no último ano e 138.60% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Immunome (IMNM) hoje, o investimento total seria de US$ 2,982.50, com base na cotação atual de US$ 29.83.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 8,877.41
Em 5 anos: US$ 7,116.25
Em 10 anos: US$ 2,982.50

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

IMNM

Immunome Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment IMNM

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING IMNM WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Immunome

Immunome Inc.

United States

20 years

2020

23

PROFIT X PRICE IMNM

Financial Results IMNM

IMNM cash flow

Asset, Revenue and Profit Growth - IMNM

IMNM balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions